Is NAD+ IV therapy worth the money?

Probably not, based on what researchers who study NAD+ actually say. No well-controlled human study has published outcome data for NAD+ IV infusions specifically, despite longevity clinics charging $200 to over $1,000 per session. The scientists closest to the research call the human evidence "pretty iffy" at best.

What the clinics are selling

NAD+, short for nicotinamide adenine dinucleotide, is a molecule every cell needs to convert food into usable energy, and its levels genuinely decline with age. That real biological fact has become the foundation for a fast-growing wellness business: IV drips that promise to replenish NAD+ directly into the bloodstream, marketed for energy, mental clarity, recovery and slower aging. NPR's reporting on the industry in May 2026 found sessions running anywhere from $200 to upwards of $1,000, with some concierge and longevity clinics charging even more for a full course. Haute Living's survey of clinic pricing put a single session at $300 to $1,000, and a full induction series of six to ten sessions at $2,000 to $8,000. That is a serious financial commitment for a treatment that, as it turns out, has almost no published human data behind the specific delivery method being sold, a pattern that shows up across how longevity clinics make money more broadly.

What the actual researchers say

This is where the gap between marketing and research becomes stark. Dr. Samuel Klein, director of the Center for Human Nutrition at Washington University School of Medicine, put it as directly as a scientist is likely to: "In rodents and mice, not in humans, NAD+ is miraculous. The data in humans are pretty iffy right now that it actually has significant benefits." Dr. Shalender Bhasin, who directs the Boston Pepper Aging Research Center at Brigham and Women's Hospital, calls the underlying hypothesis "very attractive" as an idea, but is careful to add "we are still in the early stages of human studies." Christopher Martens, director of the Delaware Center for Cognitive Aging Research, frames the whole field's problem in one line: "I think now the cart may be well ahead of the horse," adding that influencer culture "is now interfering, a little bit, with our ability to do rigorous science." None of these are fringe skeptics. They are the people actually running NAD+ studies, and their consistent message is that animal results have not yet translated into confirmed human benefit, for any delivery method.

Why the IV route specifically is shakier

Even within that cautious picture, the infusion itself has a particular problem: getting the molecule to actually do something once it's in the bloodstream. A 2019 pharmacokinetic study found that after a single IV infusion, plasma NAD+ did not rise for about two hours, while breakdown products such as nicotinamide showed up quickly, pointing to much of the dose being metabolized before it could be put to use. Rachel Pojednic, a nutritional biochemist at Stanford University who also serves as chief science officer for a national chain that sells NAD+ infusions, has acknowledged this directly: her own pilot data suggest the infusions are "very inefficient" at raising cellular NAD+ levels, because the molecule has "no easy door" into cells. That is a notable admission from someone commercially invested in the treatment, and it lines up with the independent pharmacokinetic data.

What a recent safety study found

A February 2026 study, with Pojednic as corresponding author, compared NAD+ IV infusions with NR (an oral precursor given intravenously) in a small group of 14 people and reported moderate to severe gastrointestinal symptoms, including nausea, abdominal cramping, diarrhea and vomiting, along with increased heart rate and chest pressure during some NAD+ infusions. NPR noted Pojednic's commercial tie to the infusion industry when reporting the study, and the research itself was retrospective, small and focused on tolerability rather than benefit. Pojednic argues NAD+ shouldn't be dismissed as part of the "wild wild west of the longevity wellness space," and says "real people are reporting that it seems to be helping them." That is a fair point about anecdote, but it is also exactly the kind of claim the field's own researchers say needs controlled trials, not testimonials, to confirm.

The cheaper, better-studied alternative

Oral NAD+ precursors, NR and NMN, which are the same compounds discussed in NMN and NAD supplements for aging, actually have more human trial data than the IV infusions do, including small studies in women with prediabetes, people newly diagnosed with Parkinson's disease, and those with peripheral artery disease. Bhasin says these pills appear safe across the trials conducted so far. They also cost a fraction of the price, generally $30 to $80 a month rather than hundreds of dollars per clinic visit. Independent testing has found real variability in supplement quality and label accuracy, so that route isn't risk-free either, but it starts from a stronger evidence base than the drip does.

Our take

NAD+ decline with age is real, and the hypothesis that restoring it could help is reasonable enough that serious researchers are studying it. What isn't supported yet is the specific product being sold at longevity clinics: an IV infusion with no published controlled human outcome data, a plausible mechanism for why much of the dose may go to waste, and a 2026 safety study flagging real gastrointestinal side effects. If NAD+ genuinely interests you, the oral precursors covered by actual human research are the more defensible, far cheaper place to start, and a conversation with your doctor beats a few hundred dollars spent on a drip the researchers themselves aren't sold on.

This is general information, not medical advice. Talk to a clinician before changing anything, especially if you are pregnant, nursing, or managing a condition.